Literature DB >> 26260717

Remission From Behavioral Dysregulation in a Child With PTSD After Receiving Procedural Ketamine.

Anna C Donoghue1, Mark G Roback2, Kathryn R Cullen3.   

Abstract

Ketamine, an N-methyl-D-aspartate-type glutamate receptor antagonist, has long been used for anesthesia and has recently been investigated for its rapid antidepressant effects in adults with treatment-resistant depression and posttraumatic stress disorder (PTSD). We report a case of a child with PTSD and episodes of severe aggression and emotional dysregulation that were refractory to multiple medical and behavioral interventions. This child demonstrated sustained (8-13 days) remission from these symptoms when exposed to ketamine in the context of 2 procedures. We review the sparse literature on the uses of ketamine for behavioral purposes in children. This case suggests that ketamine should be further explored as a potential treatment option for children with severe refractory behavioral aggression.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26260717      PMCID: PMC5534263          DOI: 10.1542/peds.2014-4152

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

3.  Intranasal ketamine for intermittent explosive disorder: a case report.

Authors:  Jon E Berner
Journal:  J Clin Psychiatry       Date:  2007-08       Impact factor: 4.384

4.  Prior exposure to interpersonal violence and long-term treatment response for boys with a disruptive behavior disorder.

Authors:  Chad E Shenk; Lorah D Dorn; David J Kolko; Joseph R Rausch; Salvatore P Insana
Journal:  J Trauma Stress       Date:  2014-09-30

5.  Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.

Authors:  Nanxin Li; Rong-Jian Liu; Jason M Dwyer; Mounira Banasr; Boyoung Lee; Hyeon Son; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2011-02-03       Impact factor: 13.382

6.  Children with disruptive behaviours II: clinical and community service needs.

Authors:  P L Hazell; M Tarren-Sweeney; G V Vimpani; D Keatinge; K Callan
Journal:  J Paediatr Child Health       Date:  2002-02       Impact factor: 1.954

7.  Practice parameter for the assessment and treatment of children and adolescents with reactive attachment disorder of infancy and early childhood.

Authors:  Neil W Boris; Charles H Zeanah
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-11       Impact factor: 8.829

8.  Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.

Authors:  Demitri F Papolos; Martin H Teicher; Gianni L Faedda; Patricia Murphy; Steven Mattis
Journal:  J Affect Disord       Date:  2012-11-30       Impact factor: 4.839

9.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Authors:  Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

Review 10.  Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Front Pharmacol       Date:  2013-12-27       Impact factor: 5.810

View more
  7 in total

1.  Intra-prefrontal cyclosporine potentiates ketamine-induced fear extinction in rats.

Authors:  Ahmad Mohammadi-Farani; Negin Tamasoki; Reza Rahimian
Journal:  Exp Brain Res       Date:  2021-03-05       Impact factor: 1.972

2.  Long-term increase in sensitivity to ketamine's behavioral effects in mice exposed to mild blast induced traumatic brain injury.

Authors:  Caroline A Browne; Hildegard A Wulf; Moriah L Jacobson; Mario G Oyola; T John Wu; Irwin Lucki
Journal:  Exp Neurol       Date:  2021-12-28       Impact factor: 5.330

3.  Promises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression.

Authors:  Caitlyn J Bartsch; Jacob C Nordman
Journal:  Front Behav Neurosci       Date:  2022-06-21       Impact factor: 3.617

Review 4.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

5.  Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial.

Authors:  Alisher R Dadabayev; Sonalee A Joshi; Mariam H Reda; Tamar Lake; Mark S Hausman; Edward Domino; Israel Liberzon
Journal:  Chronic Stress (Thousand Oaks)       Date:  2020-12-22

Review 6.  Ketamine: 50 Years of Modulating the Mind.

Authors:  Linda Li; Phillip E Vlisides
Journal:  Front Hum Neurosci       Date:  2016-11-29       Impact factor: 3.169

7.  Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019.

Authors:  John Martin Corkery; Wan-Chu Hung; Hugh Claridge; Christine Goodair; Caroline S Copeland; Fabrizio Schifano
Journal:  J Psychopharmacol       Date:  2021-06-05       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.